Test Price
2,800 AED✅ Home Collection Available
SYNE4 Gene Deafness (Autosomal Recessive Type 76) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Diagnostic Sensitivity: 99.9% via ISO-Accredited Next-Generation Sequencing (NGS) – clinically validated for DFNB76 hereditary hearing loss.
- Test Price: 2,800 AED inclusive of post-test telephonic genetic counselling.
- Turnaround Time: 3 to 4 weeks from specimen receipt at the laboratory.
- Sample Type: Peripheral whole blood, buccal swab, or FTA card – collected via VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- Insurance: Direct billing verification available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The SYNE4 gene NGS test screens all coding exons and flanking intronic regions for pathogenic and likely pathogenic variants associated with autosomal recessive deafness type 76 (DFNB76). The SYNE4 gene encodes a spectrin-repeat protein essential for inner ear hair cell structural integrity; biallelic loss-of-function mutations disrupt cochlear function, leading to congenital or early-onset sensorineural hearing loss. This test provides a definitive molecular diagnosis, enabling tailored audiological intervention, family cascade screening, and genetic counselling.
| Feature | Our Test (NGS – SYNE4 Full Gene) | Closest Alternative (Sanger Sequencing Panel) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – whole gene coverage with >100× depth | Sanger sequencing – limited to known hotspot exons only |
| Detection Rate | >99% of coding variants (SNVs, indels, splice-site) | ~85% (targeted regions only; may miss novel variants) |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Price | 2,800 AED | ≥2,500 AED (genetic counselling often billed separately) |
| Post‑Test Genetic Counselling | Included (telephonic interpretation session) | Usually charged as an additional consultation |
Physician Insight & Safety Protocols
"Confirming a molecular diagnosis for DFNB76 through comprehensive NGS analysis of SYNE4 is essential for accurate prognosis and recurrence risk assessment. However, this genetic test must be interpreted alongside a full audiological workup, including otoacoustic emissions and auditory brainstem response, and does not replace emergency evaluation for sudden hearing loss or acute vestibular symptoms. Early referral to a multidisciplinary team—genetics, ENT, and speech therapy—remains the cornerstone of optimal patient outcomes."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication & Clinical Precautions
Do not discontinue, adjust, or initiate any prescribed medication, including ototoxic drugs, without direct consultation with your treating physician. This genetic test does not assess drug-induced hearing loss and must not be used as a standalone guide for therapeutic decisions.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion – Informed Consent: Individuals unable to provide informed consent are not eligible; for minors, written parental or legal guardian consent is mandatory in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion – Bleeding Risk: Active severe bleeding disorder or coagulopathy requires physician clearance before venipuncture.
- Emergency Red Flags – Do Not Rely on This Test If: Sudden or rapidly progressive hearing loss, acute vertigo with fever, recent head trauma, otorrhea, or any neurological emergency. Seek immediate care at the nearest hospital emergency department.
Patient FAQ & Clinical Guidance
1. What does the SYNE4 gene test detect?
This test identifies disease-causing mutations in the SYNE4 gene responsible for autosomal recessive deafness type 76 (DFNB76). The SYNE4 gene encodes a protein critical for inner ear hair cell structure; biallelic pathogenic variants lead to congenital or early-onset sensorineural hearing loss. The test uses NGS to analyze all coding exons and confirm a molecular diagnosis or carrier status.
2. How is the sample collected for this genetic test?
A simple peripheral blood draw, buccal swab, or FTA card sample is collected by our trained phlebotomist during a scheduled home visit. The specimen is transported under temperature-controlled cold-chain conditions to our ISO-accredited laboratory. No fasting or special preparation is required; pre-test genetic counselling can be conducted virtually before collection.
3. How long do results take and what is the cost?
Results are typically available within 3 to 4 weeks from sample receipt. The total cost is 2,800 AED, inclusive of telephonic post-test genetic counselling. The final report includes variant classification (pathogenic, likely pathogenic, or variant of uncertain significance), clinical correlation, and recommendations for family cascade testing. Insurance direct billing is verified via WhatsApp prior to your appointment.
4. Who should consider this genetic test?
This test is indicated for individuals with congenital or early-onset sensorineural hearing loss of unknown etiology, families with a history of autosomal recessive deafness, couples planning a family who are known carriers of a SYNE4 variant, and individuals seeking clarification of a previous inconclusive genetic result. It is also appropriate for prenatal or preimplantation genetic testing in at-risk couples following specialist consultation.
5. Will the test results affect my current treatment or hearing aids?
The test result itself does not alter ongoing audiological management. However, a confirmed molecular diagnosis may guide prognosis, inform eligibility for cochlear implantation, and direct surveillance for associated comorbidities. Your ENT specialist and genetic counsellor will review the report together with you to adjust the management plan as needed. Continue all current therapies unless advised otherwise by your physician.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of personal genomic and health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating telehealth, electronic health records, and digital data security in healthcare settings.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring patient safety, informed consent, and clinical accountability throughout the testing pathway.
All genetic data is encrypted, access-controlled, and retained only for the legally mandated period. Patients have the right to access, rectify, or request deletion of their data in accordance with PDPL provisions.
Clinical & Logistical Metadata
| Test Name | SYNE4 Gene Deafness (Autosomal Recessive Type 76) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood / Buccal Swab / FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coding Exons & Flanking Intronic Regions |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 101430-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians